Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

v3.21.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Schedule of Other Current Assets

Other current assets consisted of the following as of March 31, 2021 and December 31, 2020:

 

    March 31, 2021     December 31, 2020  
    (unaudited)        
Lab supply inventory   $ 2,227     $ 2,052  
Prepaid expenses     560       625  
Other     188       45  
Total other current assets   $ 2,975     $ 2,722  

Schedule of Basic and Diluted Net Loss Per Share

A reconciliation of the number of shares of common stock, par value $0.01 per share, used in the calculation of basic and diluted loss per share for the three-month periods ended March 31, 2021 and 2020 is as follows:

 

    Three Months Ended  
    March 31,  
    2021     2020  
    (unaudited)  
Basic weighted average number of common shares     4,089       4,004  
Potential dilutive effect of stock-based awards     -       -  
Diluted weighted average number of common shares     4,089       4,004  

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

The Company’s Series B Preferred Stock, on an as converted basis of 7,833,334 shares for the three- months ended March 31, 2021, and the following outstanding stock-based awards and warrants, were excluded from the computation of the effect of dilutive securities on loss per share for the following periods as they would have been anti-dilutive (rounded to thousands):

 

    Three Months Ended  
    March 31,  
    2021     2020  
    (unaudited)  
Options     1,061       578  
Restricted stock and restricted stock units (RSUs)     395       42  
Warrants     1,405       1,420  
      2,861       2,040